参考文献:
The National Lung Screening Trial Research Team. (2011). Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. New England Journal of Medicine, 365(5), 395-409.
de Koning, H. J., van der Aalst, C. M., de Jong, P. A., et al. (2020). Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. New England Journal of Medicine, 382(6), 503-513.
U.S. Preventive Services Task Force (USPSTF). (2021). Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA, 325(10), 962-970.
National Comprehensive Cancer Network (NCCN). (2023). NCCN Clinical Practice Guidelines in Oncology: Lung Cancer Screening. Version 1.2023.
Sung, H., Ferlay, J., Siegel, R. L., et al. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209-249.
Zheng, R., Zhang, S., Zeng, H., et al. (2022). Cancer incidence and mortality in China, 2016. Journal of the National Cancer Center.
Goldstraw, P., Chansky, K., Crowley, J., et al. (2016). The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 11(1), 39-51.
Aberle, D. R., Adams, A. M., Berg, C. D., et al. (2011). Baseline characteristics of participants in the randomized national lung screening trial. Journal of the National Cancer Institute, 103(24), 1834-1846.